Related Experiment Video
Updated: Mar 29, 2026
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
Precision Medicine for Molecularly Targeted Agents and Immunotherapies in Early-Phase Clinical Trials
Juanita Lopez1, Sam Harris1, Desam Roda1
1Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, London, UK.
Abstract:
Precision medicine in oncology promises the matching of genomic, molecular, and clinical data with underlying mechanisms of a range of novel anticancer therapeutics to develop more rational and effective antitumor strategies in a timely manner. However, despite the remarkable progress made in the understanding of novel drivers of different oncogenic processes, success rates for the approval of oncology drugs remain low with substantial fiscal consequences. In this article, we focus on how recent rapid innovations in technology have brought greater clarity to the biological and clinical complexities of different cancers and advanced the development of molecularly targeted agents and immunotherapies in clinical trials. We discuss the key challenges of identifying and validating predictive biomarkers of response and resistance using both tumor and surrogate tissues, as well as the hurdles associated with intratumor heterogeneity. Finally, we outline evolving strategies employed in early-phase trial designs that incorporate omics-based technologies.
Insights
Precision medicine aims to match patient data with cancer therapies for better outcomes. Despite technological advances, challenges in biomarker validation and tumor heterogeneity impact oncology drug approvals.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Precision medicine in oncology aims to integrate genomic, molecular, and clinical data with novel anticancer therapeutics.
- Despite advances in understanding oncogenic processes, oncology drug approval rates remain low, incurring significant costs.
Purpose of the Study:
- To discuss how technological innovations are enhancing the development of targeted agents and immunotherapies in clinical trials.
- To address challenges in identifying and validating predictive biomarkers for treatment response and resistance.
- To outline evolving strategies in early-phase trial designs incorporating omics-based technologies.
Main Methods:
- Review of recent technological innovations in cancer research.
- Discussion of challenges in biomarker identification and validation using tumor and surrogate tissues.
- Analysis of hurdles related to intratumor heterogeneity.
- Examination of early-phase trial designs incorporating omics data.
Main Results:
- Technological advancements provide greater clarity on cancer complexities, aiding molecularly targeted agent and immunotherapy development.
- Key challenges include validating predictive biomarkers and addressing intratumor heterogeneity.
- Evolving strategies in early-phase trials are incorporating omics-based technologies.
Conclusions:
- Integrating omics data and addressing biomarker and heterogeneity challenges are crucial for improving precision medicine in oncology.
- Novel trial designs are essential for the timely and effective development of anticancer therapeutics.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:50Combination Therapies and Personalized Medicine
01:29Pharmacogenomics: Identification of New Drug Targets
01:27Tumor Immunotherapy